PsA Secukinumab XCT Structural Progression Study

• Status: Recruiting
• Trial end date: 2022-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Psoriatic arthritis is related with chronic inflammation and progressive radiographic damages, and it in turn lead to disability and loss in function-ability. Recent advance in treatment pathway through anti IL-17 gives promising clinical improvement. Yet, its effect on radiographic progression remains uncertain. This study aimed to ascertain the effect of secukinumab on structural progression in PsA by evaluation through high resolution peripheral quantative computed tomography (HRpqCT).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese University of Hong Kong
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

1. ≥18 years old;

2. without severe deformity in MCP joints which would influence the longitudinal assessment of HR-pQCT;

3. with active disease, which is defined as three or more than tender joints and three or more than swollen joints, despite previous treatment with nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs.

Exclusion Criteria:

1. limited in ability to perform usual self-care, vocational, and avocational activities;

2. pregnancy;

3. previous therapy with biologic;

4. the presence of active inflammatory diseases other than PsA;

5. active infection in 2 weeks before randomization or a history of ongoing, chronic, or recurrent infections including tuberculosis;

6. history of hepatitis B & C;

7. history of malignant disease within the past 5 years (excluding basal cell carcinoma or actinic keratosis, in-situ cervical cancer, or non-invasive malignant colon polyps);

8. contraindications to secukinumab.